New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Cadrenal Therapeutics, Inc. Common Stock
CVKD
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

33M

Biotechnology

Next Earning date - 08 May 2025

33M

Biotechnology

Next Earning date - 08 May 2025

16.80USD

Shape-0.20 ( -1.18%)
Market Closed (as of Apr 25, 20:00 EDT)
favorite-chart

Relative Strenght

favorite-chart

Volume Buzz

-63%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

27%
OverviewChart

Quote Panel

Shape
Updated April 27, 2025
1W 3.83 % 1M -8.99 % 3M -11.49 % 1Y 148.15 %

Key Metrics

Shape

  • Market Cap

    32.59M

  • Shares Outstanding

    1.94M

  • Share in Float

    1.31M

  • Dividende

    0

  • Earning Date

    08 May 2025

  • Price Target

    16.8

  • Average Volume

    33785

  • Beta

    1.455

  • Range

    5.7-22.901

  • Industry

    Biotechnology

  • Website

    https://www.cadrenal.com

  • Sector

    Healthcare

Fundamentals

Shape

Relative Strength

Shape

CVKD

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape
0

$4.33

Shape-26%

2025-EPS

0

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Buy

Price Target

0.00(-100.00%)

Number of analyst

0

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q1.23

arrow
arrow

N/A

-6.62
vs -0.02

Q2.23

arrow
arrow

N/A

-1.35
vs -0.04

Q3.23

arrow
arrow

N/A

-1.05
vs -0.09

Q4.23

arrow
arrow

N/A

-0.75
vs -0.41

Q1.24

arrow
arrow

N/A

-1.50
vs -6.62

Q2.24

arrow
arrow

N/A

-2.25
vs -1.35

Q3.24

arrow
arrow

N/A

-2.18
vs -1.05

Q4.24

arrow
arrow

N/A

-2.74
vs -0.75

Q1.25

arrow
arrow

N/A

-2.15
vs -1.50

Q2.25

arrow
arrow

N/A

-1.26
vs -2.25

Sales GrowthShape

status-upYoY

Current

Estimates

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

2.8K  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Q3.24

arrow
arrow

NA

NA  vs NA

Q4.24

arrow
arrow

-100%

NA  vs 2.8K

Return on EquityShape

status-upQoQ

Q1.23

arrow
arrow

-127%

-1.27
vs 0.9

Q2.23

arrow
arrow

-32%

-0.32
vs -1.27

Q3.23

arrow
arrow

-12%

-0.12
vs -0.32

Q4.23

arrow
arrow

-15%

-0.15
vs -0.12

Q1.24

arrow
arrow

-27%

-0.27
vs -0.15

Q2.24

arrow
arrow

-60%

-0.60
vs -0.27

Q3.24

arrow
arrow

-71%

-0.71
vs -0.60

Q4.24

arrow
arrow

-56%

-0.56
vs -0.71

Institutionnal OwnershipShape

status-up

Earnings Growth

Latest News

CVKD

businesswire.com

8 hours ago

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
CVKD

businesswire.com

8 hours ago

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
CVKD

businesswire.com

9 hours ago

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq
CVKD

prnewswire.com

9 hours ago

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
CVKD

prnewswire.com

9 hours ago

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
CVKD

prnewswire.com

9 hours ago

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE